A Single-arm Study of Trastuzumab Deruxtecan (T-DXd) Monotherapy for Patients With HER2-expressing Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Who Have Received 2 or More Prior Regimens (DESTINY-Gastric06)
Latest Information Update: 09 May 2024
At a glance
- Drugs Trastuzumab-deruxtecan (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms DG-06
- Sponsors AstraZeneca
- 06 May 2024 Status changed from active, no longer recruiting to completed.
- 01 Dec 2023 According to Daiichi Sankyo Company Media Release, data from this study will be presented at the 2023 ESMO Asia Congress.
- 03 Jan 2023 Planned primary completion date changed from 28 Jul 2023 to 28 Feb 2024.